Header Image

Continuing Medical Education

CME Calculator

If viewing on a phone- turn to landscape mode 

**Go here for SEC Pre-meeting CME**

** Not all hours are possible due to overlapping sessions**

Reset Table

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The American Academy of Ophthalmology and the American Association for Pediatric Ophthalmology and Strabismus. The American Academy of Ophthalmology is accredited by the ACCME to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this live activity for a maximum of 31.25 AMA PRA Category 1 Credits™. (The SEC pre-day program is eligible for up to 6.5 AMA PRA Category 1 Credits™.) Physicians should claim only the credit commensurate with the extent of their participation in each activity.

Overall Meeting Goals

Upon completion of this activity, participants will be able to:

  • Describe recent medical advances in the diagnosis, management, and treatment of conditions encountered in the practice of pediatric ophthalmology and strabismus
  • Discuss improved techniques, compare/contrast methods, and review clinical research and advances in order to provide the best possible treatment options and care to patients
  • Describe aspects of professionalism that will assist in practice of pediatric ophthalmology and strabismus
  • Describe new techniques in select aspects of surgery pertinent to pediatric ophthalmology and strabismus

Specific Learning Objectives

  1. Cite most recent data from randomized controlled clinical trials in the diagnosis and management of amblyopia.
  2. Describe new preoperative evaluation techniques and surgical strategies to improve outcomes in patients with comitant, non-paretic strabismus.
  3. Compare new surgical techniques for complicated strabismus (restrictive, paretic, miswiring syndromes, scarring, incomitance, etc) to decrease re-operation rate.
  4. Outline up-to-date patient selection criteria to identify children undergoing cataract surgery who should receive intraocular lenses.
  5. Recognize new treatment techniques for pediatric glaucoma, retinal, and oculoplastic and orbital disease and make appropriate sub-subspecialty referrals for such cases.
  6. Describe new treatment strategies to decrease the incidence of significant visual loss from high risk ROP.
  7. Recognize pediatric ophthalmic disease of neurologic origin and describe the process for appropriate referrals to pediatric neurology.
  8. Utilize the latest resources for discussion of visual development, epidemiology of pediatric eye disease, learning disabilities, vision screening strategies with other physicians and members of the lay community.
  9. Identify current coding rules and regulations for pediatric eye diseases.
  10. Recognize current laboratory research with potential translation applicability to pediatric ophthalmology.
  11. Describe the role of OCT imaging in the diagnosis and treatment of optic nerve, retinal and anterior segment diseases.

FDA Status Disclaimer

The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use in clinical practice, and to use these products with appropriate patient consent and in compliance with applicable law. The AAPOS provides the opportunity for material to be presented for educational purposes only. The material represents the approach, ideas, statement, or opinion of the presenter and/or author, not necessarily the only or best method or procedure in every case, nor the position of AAPOS. The material is not intended to replace a physician’s own judgement or give specific advice for case management. AAPOS specifically disclaims any and all claims that may arise out of the use of any technique demonstrated or described in any material by any presenter and/or author, whether such claims are asserted by a physician or any other person. Please note: The AAPOS requires all presenters and/or authors to disclose any drug or device that is not approved for use by the FDA in the manner discussed during any oral presentation and/or on all written materials.